In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Lung Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Dietary Intervention for Patients Receiving Chemoradiotherapy for Lung Cancer
    (Posted: 11/13/2012) - In this phase I clinical trial, patients with advanced non-small cell lung cancer who are about to undergo chemoradiation therapy will consume a very low-carbohydrate ketogenic diet for the duration of their treatment.
  • Genetically Engineered Immunotherapy for Advanced Cancer
    (Posted: 08/07/2012) - In this trial, doctors will collect T lymphocytes from the blood of patients with advanced mesothelin-expressing cancer and genetically engineer these cells to recognize mesothelin. The gene-engineered cells will then be multiplied and infused into the patients to fight their cancer.
  • Surgical and Radiation Therapies for High-Risk Early Lung Cancer
    (Posted: 05/01/2012) - Patients with high-risk operable stage I lung cancer will be randomly assigned to undergo either sublobar resection, with or without brachytherapy, or stereotactic body radiation therapy.
  • Virus Therapy for Extensive-Stage Small Cell Lung Cancer
    (Posted: 04/03/2012) - In this clinical trial, patients with extensive-stage small cell lung cancer who have received platinum-based chemotherapy will be randomly assigned to receive Seneca Valley virus-001 intravenously or an intravenous placebo.
  • Comparing Lung Cancer Targeted Therapies Based on KRAS Mutation Status
    (Posted: 08/09/2011) - In this trial, doctors will test the KRAS mutation status of tumors in patients with advanced non-small cell lung cancer whose disease has progressed during or after chemotherapy; they will then randomly assign the patients to either AZD6244 plus erlotinib or either drug alone, depending on KRAS status of their tumors.
1 2 3 4  Next >